Novo Nordisk Has A Plan To Get Wegovy Launch Back On The Rails
The company is targeting revenues of DKK25bn ($3.66bn) from Wegovy for obesity in 2025, with plans to amp up the US launch this year following an initial supply disruption.
You may also be interested in...
Wegovy and Saxenda surpass cost effectiveness thresholds at current prices, while two widely unused drugs, Qysmia and Contrave, are cost-effective at accepted benchmarks, according to a draft report from the Institute for Clinical and Economic Review.
Unrelated US FDA inspection led contract manufacturer to stop filling Wegovy syringes before alternate manufacturing facilities became available.
Wegovy is set to join Saxenda as the company’s second EU approved drug for obesity, helping it corner the region’s weight-management market, once the company gets its supply back on track.